Published in Alzheimers Res Ther on June 02, 2014
Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry (2014) 1.00
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther (2015) 0.86
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies. Sci Rep (2015) 0.83
N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42. J Am Chem Soc (2015) 0.81
Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes. Biochim Biophys Acta (2016) 0.77
An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction. J Immunol Res (2016) 0.75
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy. J Biol Chem (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol (1991) 6.62
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science (1989) 5.73
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Potent antibody therapeutics by design. Nat Rev Immunol (2006) 4.87
Reshaping human antibodies for therapy. Nature (1988) 4.82
Making antibody fragments using phage display libraries. Nature (1991) 4.61
Accurate modeling of protein conformation by automatic segment matching. J Mol Biol (1992) 4.39
Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 4.19
Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell (2013) 4.02
A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron (2012) 3.32
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng (1996) 2.44
Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci U S A (1991) 2.42
Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 2.39
A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A (1989) 2.23
Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc Natl Acad Sci U S A (2008) 1.99
Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur J Biochem (2002) 1.99
Preventing Alzheimer's disease. Science (2012) 1.94
Reshaping human antibodies: grafting an antilysozyme activity. Science (1988) 1.92
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
A new structural model of Aβ40 fibrils. J Am Chem Soc (2011) 1.78
Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci (2008) 1.70
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A (2007) 1.68
Accurate prediction of the stability and activity effects of site-directed mutagenesis on a protein core. Nature (1991) 1.65
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement (2012) 1.53
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol (2005) 1.51
Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet (1994) 1.50
Modeling antibody hypervariable loops: a combined algorithm. Proc Natl Acad Sci U S A (1989) 1.50
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci (2012) 1.36
Molecular basis for passive immunotherapy of Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.26
Alzheimer's drugs take a new tack. Nature (2012) 1.20
Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng (1991) 1.18
Antibody modeling: implications for engineering and design. Methods (2000) 1.18
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol (2008) 1.17
Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci (2012) 1.16
When binding is enough: nonactivating antibody formats. Curr Opin Immunol (2008) 1.15
Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol (2008) 1.14
Alzheimer's research. Stopping Alzheimer's before it starts. Science (2012) 1.09
Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res (2006) 1.08
Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci (2011) 1.08
Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A (1991) 1.07
Solution structure of residues 1-28 of the amyloid beta-peptide. Biochemistry (1994) 1.06
Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol Immunol (2008) 1.03
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep (2013) 1.02
Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement (2010) 0.99
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
Structures of Abeta-related peptide--monoclonal antibody complexes. Biochemistry (2009) 0.82
YAC vectors. Humanizing the mouse genome. Curr Biol (1994) 0.80